These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38710206)

  • 1. Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Merza Mohammad TA; Merza Mohammad TA; Salman DM; Jaafar HM
    Pharmacopsychiatry; 2024 Jul; 57(4):205-214. PubMed ID: 38710206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.
    El-Haggar SM; Eissa MA; Mostafa TM; El-Attar KS; Abdallah MS
    Psychother Psychosom; 2018; 87(6):331-339. PubMed ID: 30205379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
    Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
    J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
    Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
    J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.
    Abdallah MS; Mosalam EM; Zidan AA; Elattar KS; Zaki SA; Ramadan AN; Ebeid AM
    Neurotherapeutics; 2020 Oct; 17(4):1897-1906. PubMed ID: 32500486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression.
    Ranjbar E; Shams J; Sabetkasaei M; M-Shirazi M; Rashidkhani B; Mostafavi A; Bornak E; Nasrollahzadeh J
    Nutr Neurosci; 2014 Feb; 17(2):65-71. PubMed ID: 23602205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial.
    Hoobehfekr S; Moghaddam HS; Shalbafan M; Hashemi MG; Pirmoradi MM; Sakenian A; Poopak A; Kashefinejad S; Yarahmadi M; Akhondzadeh S
    Psychiatry Clin Neurosci; 2021 Feb; 75(2):57-62. PubMed ID: 33247483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
    Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
    Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pentoxifylline for the treatment of bipolar I/II patients with treatment-resistant depression: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
    Mohammad TAM; Mohammad TAM; Shawis TN
    Brain Res Bull; 2024 Oct; 216():111047. PubMed ID: 39128677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
    Yu JJ; Pei LB; Zhang Y; Wen ZY; Yang JL
    J Clin Psychopharmacol; 2015 Aug; 35(4):406-10. PubMed ID: 26066335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.
    Lyoo IK; Yoon S; Kim TS; Hwang J; Kim JE; Won W; Bae S; Renshaw PF
    Am J Psychiatry; 2012 Sep; 169(9):937-945. PubMed ID: 22864465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Salardini E; Zeinoddini A; Mohammadinejad P; Khodaie-Ardakani MR; Zahraei N; Zeinoddini A; Akhondzadeh S
    J Psychiatr Res; 2016 Apr; 75():24-30. PubMed ID: 26800392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Farajollahi-Moghadam M; Sanjari-Moghaddam H; Ghazizadeh Hasemi M; Sanatian Z; Talaei A; Akhondzadeh S
    Int Clin Psychopharmacol; 2021 May; 36(3):140-146. PubMed ID: 33724254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.